2nd T-Cell Engager for Autoimmune Disease Summit Returns in 2026 to Advance the Next Wave of Autoimmune Therapeutics
Industry leaders from Gilead Sciences, Sanofi, Eli Lilly, Takeda, Bristol Myers Squibb, Novartis and more will gather to address safety, translational predictability, biomarker strategy and durable immune reset in autoimmune T-cell engager development.
The 2nd T-Cell Engager for Autoimmune Disease Summit will return in 2026 as the only industry-dedicated meeting focused exclusively on advancing T-cell engagers for autoimmune disease.
As autoimmune T-cell engagers continue to rapidly progress into the clinic, the field is moving beyond first-generation B-cell depletion and proof-of-concept studies. Developers are now facing a new wave of challenges around safety, translational predictability, dosing strategy, biomarker-driven development and achieving durable immune reset.
The 2026 summit agenda reflects this accelerated evolution, with a refreshed programme designed to support discovery, translational, clinical and immunology teams as they benchmark next-generation approaches and translate emerging clinical insights into more precise, effective and durable autoimmune therapies.
This year’s programme will feature 15+ new expert speakers from leading organizations including Gilead Sciences, Sanofi, Eli Lilly, Takeda, Bristol Myers Squibb, Novartis and more, sharing exclusive insights across discovery, translational, clinical and regulatory development.
New for 2026, the summit will also include dedicated clinical data-focused sessions exploring emerging safety, efficacy, dosing and biomarker learnings from first-wave autoimmune T-cell engager programmes. These discussions are designed to help accelerate next-generation development strategies and address the key hurdles facing teams as assets advance toward and through the clinic.
Expanded scientific coverage will include precision peptide-HLA target discovery, autoreactive B-cell targeting, CD3 tuning, trispecific engineering, tissue penetration, T-cell fitness and immune reset strategies.
In addition, the 2026 meeting will introduce two brand-new deep-dive workshops focused on autoimmune T-cell engager engineering, CRS mitigation, translational modelling, predictive biomarkers and clinical development strategy.
The summit will also provide more than 8 hours of dedicated networking, including speed networking, interactive roundtables, collaborative discussion sessions and a scientific poster session, connecting over 80 discovery, translational, clinical and immunology leaders from across the autoimmune T-cell engager community.
With the field entering a critical stage of clinical translation, the 2nd T-Cell Engager for Autoimmune Disease Summit will offer a dedicated forum for industry leaders to assess the latest scientific advances, benchmark development strategies and help shape the next generation of autoimmune-targeted T-cell engager therapeutics.
The full 2026 agenda is now available to download.
Access the agenda here: https://ter.li/6k2r34t4
To join the leading minds advancing autoimmune T-cell engager development, register your place today and secure your seat at the only industry-dedicated forum focused exclusively on this fast-evolving field.
Register here: https://ter.li/7bepnxtf